(Q40473633)

20 September 2017

Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. (English)

1 reference

20 September 2017

1 reference

1 reference

6

1 reference

20 September 2017

Jan Bouchal

1

1 reference

20 September 2017

Karl R N Baumforth

2

1 reference

20 September 2017

Michaela Sváchová

3

1 reference

20 September 2017

Paul G Murray

4

1 reference

20 September 2017

Erwin von Angerer

5

1 reference

20 September 2017

1 January 2005

1 reference

Journal of Pharmacy and Pharmacology

20 September 2017

1 reference

20 September 2017

57

1 reference

20 September 2017

1

1 reference

20 September 2017

83-92

1 reference

Androgen receptor as a target in androgen-independent prostate cancer

20 September 2017

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

p53 oncogene mutations in three human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Telomerase in the human organism

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

c-Myc target genes involved in cell growth, apoptosis, and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

In vivo regulation of hTERT expression and telomerase activity by androgen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Telomere loss: mitotic clock or genetic time bomb?

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

The Rab6-binding kinesin, Rab6-KIFL, is required for cytokinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

An overview of animal toxicology studies with bicalutamide (ICI 176,334).

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Specific association of human telomerase activity with immortal cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Bicalutamide dosages used in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Antiandrogen-induced cell death in LNCaP human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Identification of a new acute phase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Secondary hormonal therapies in the treatment of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Statistical analysis of high-density oligonucleotide arrays: a multiplicative noise model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

An evaluation of bicalutamide in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Androgen-induced cell growth and c-myc expression in human non-transformed epithelial prostatic cells in primary culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Test of significant differences with a priori probability in microarray experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357055164

21 January 2018

Identifiers

DOI

10.1211/0022357055164

1 reference

20 September 2017

1 reference